Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry
The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
The liver is critical to consider during drug development because of its central role in the handling of xenobiotics, a process which often leads to localized and/or downstream tissue injury. Our ability to predict human clinical safety outcomes with animal testing is limited due to species differences in drug metabolism and disposition, while traditional human in vitro liver models often lack the necessary in vivo physiological fidelity. To address this, increasing numbers of liver microphysiological systems (MPS) are being developed, however the inconsistency in their optimization and characterization often leads to models that do not possess critical levels of baseline performance that is required for many pharmaceutical industry applications. Herein we provide a guidance on best approaches to benchmark liver MPS based on 3 stages of characterization that includes key performance metrics and a 20 compound safety test set. Additionally, we give an overview of frequently used liver injury safety assays, describe the ideal MPS model, and provide a perspective on currently best suited MPS contexts of use. This pharmaceutical industry guidance has been written to help MPS developers and end users identify what could be the most valuable models for safety risk assessment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These consortia not only promote MPS and OoC adoption but also generate lists of reference compounds relevant to various organ systems (Ainslie et al., 2019; Baudy et al., 2020; Hardwick et al., 2020; Peters et al., 2020; Phillips et al., 2020; Pointon et al., 2021).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Baudy et al., 2020
In the citing paper
“Guided by the IQ MPS affiliate’s roadmap on liver MPS19, which states that in vitro models for predicting drug-induced liver injury (DILI) that meet its guidelines are more likely to exhibit higher predictive validity than those that do not”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
In the citing paper
“Albumin and urea production are widely accepted as functional markers for cultured hepatocytes with the goal of reaching computed production levels observed in human liver in vivo (~20–105 µg and 56–159 µg per 106 hepatocytes per day, respectively)19,26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Heroux, J., & Gharib, A. M. (2008) · Molecular Imaging in Oncology · doi:10.3109/9781420019957-3 · Cited by 2,187
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
R EGULATION OF E NZYMES OF THE U REA C YCLE AND A RGININE M ETABOLISM
Morris, S. M. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110801.140547 · Cited by 725
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
Barst, R. J., Langleben, D., Frost, A., Horn, E. M., Oudiz, R., Shapiro, S., McLaughlin, V., Hill, N., Tapson, V. F., Robbins, I. M., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-957oc · Cited by 706
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Research works printed but not linked: 15
- R. Becker , A.Chakravarty , D.Cho , O.Faris , S.Fitzpatrick , N.Hunter , I.Irony , S.Lababidi , C.Leptak , W.Mattes , E.Mishina , K.O'Callaghan , M.Pacanowski , E.Papadopoulos , V.Peiris , R.Puri , M.Robb , H.Rogers , R.Sherman , R.Sridhara , R.Temple , A.Trentacosti , P.Turfle , S.Wang , H.Hamilton , P.McInnes , L.McShane and M.Shah , BEST (Biomarkers, EndpointS, and other Tools) Resource , Silver Spring (MD) , 2018
- Kizawa, 2017, Biochem. Biophys. Rep., 10, 186
- Chen, 2013, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
- Hosey, 2016, AAPS J., 18, 251, 10.1208/s12248-015-9845-2 · DOI
- Shah, 2015, Toxicol. Sci., 147, 500, 10.1093/toxsci/kfv152 · DOI · Paper page
- Kock, 2014, Drug Metab. Dispos., 42, 665, 10.1124/dmd.113.054304 · DOI · Paper page
- Morgan, 2010, Toxicol. Sci., 118, 485, 10.1093/toxsci/kfq269 · DOI · Paper page
- Aleo, 2014, Hepatology, 60, 1015, 10.1002/hep.27206 · DOI · Paper page
- Proctor, 2017, Arch. Toxicol., 91, 2849, 10.1007/s00204-017-2002-1 · DOI · Paper page
- Bell, 2016, Sci. Rep., 6, 25187, 10.1038/srep25187 · DOI · Paper page
- Ballmer, 1990, Am. J. Physiol., 259, E797
- Hovens, 1994, Ned. Tijdschr. Geneeskd., 138, 363
- Prior, 2003, J. Psychiatry Neurosci., 28, 99
- Kostrubsky, 2000, Drug Metab. Dispos., 28, 1192
- Stork, 1997, J. Toxicol., 35, 105
Cited by
Items 101–151 of 151
Pin, C., Collins, T. A., Gibbs, M. A., & Kimko, H. H. C. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00580-2 · Cited by 6
Shi, Q., Schnackenberg, L. K., Ren, L., Papineau, K. S., Oliphant, J. M., Avigan, M., Ewart, L. C., Sauld, J. F. K., Dai, E., Brown, P. C., et al. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.111735 · Cited by 5
LaFollette, M. R., Baran, S. W., Curley, J. L., Dickinson, A. M., Frazier, T. P., Hobi, N., Huang, M.-I., Hutter, V., Maisonneuve, B. G. C., Marsh, G., et al. (2025) · Alternatives to Laboratory Animals · doi:10.1177/02611929241310566 · Cited by 5
Variability in Human In Vitro Enzyme Kinetics
Gibson, C. R., Wang, Y.-H., Varkhede, N. R., & Ma, B. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_16 · Cited by 5
Sugiura, S., Satoh, T., Shin, K., Onuki-Nagasaki, R., & Kanamori, T. (2022) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2022.07.001 · Cited by 5
Editorial overview of the special issue on application of tissue chips in toxicology
Rusyn, I., & Roth, A. B. (2021) · Toxicology · doi:10.1016/j.tox.2021.152687 · Cited by 5
“Still, it is acknowledged that the inconsistency in the optimization and characterization of liver MPS often leads to models that do not possess critical levels of baseline performance that is required for many pharmaceutical industry and broader toxicology applications (Baudy et al. 2020).”
BackgroundSelf-citationIsolated Fragments of Intact Microvessels: Tissue Vascularization, Modeling, and Therapeutics
Strobel, H. A., Moss, S. M., & Hoying, J. B. (2024) · Microcirculation · doi:10.1111/micc.12852 · Cited by 4
A novel perfusion culture system for screening mitochondrial toxicity in primary mouse hepatocytes
Yamamoto, C., Takemura, A., Ishii, S., Doi, A., Saito, I., Yamada, H., Sakai, Y., Matsunaga, T., & Ito, K. (2022) · The Journal of Toxicological Sciences · doi:10.2131/jts.47.13 · Cited by 4
A high-throughput microphysiological system to quantify key events leading to liver fibrosis
Schmidt, S., & Suter-Dick, L. (2025) · Toxicology · doi:10.1016/j.tox.2025.154248 · Cited by 3
Nitsche, K. S., Carmichael, P. L., Bakker, W., Bouwmeester, H., & Müller, I. I. (2025) · Toxicology · doi:10.1016/j.tox.2025.154364 · Cited by 4
Nitsche, K. S., Sakolish, C., Carmichael, P. L., Hewitt, P. G., Bajaj, P., Ferguson, S., Lloyd, S. M., Wilson, S. S., Bouwmeester, H., & Rusyn, I. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04263-1 · Cited by 6
“We also found that HepaRG can be used for longer-term cultures, especially in PhysioMimix LC12 where the stability of high drug metabolism function, for both CYP activity and bile acid conjugation, is essential to model chemical-induced disease states (Baudy et al. 2020 ; Vinken 2018).”
InfluentialSelf-citationAdvanced human liver models for the assessment of drug-induced liver injury
Mun, S. J., Lee, J., Shin, Y., & Son, M. J. (2022) · Organoid · doi:10.51335/organoid.2022.2.e17 · Cited by 4
Scheidecker, B., Poulain, S., Sugimoto, M., Arakawa, H., Kim, S. H., Kawanishi, T., Kato, Y., Danoy, M., Nishikawa, M., & Sakai, Y. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28653 · Cited by 5
Tokito, F., Kiyofuji, M., Choi, H., Nishikawa, M., Takezawa, T., & Sakai, Y. (2024) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2024.01.017 · Cited by 3
Candarlioglu, P. L., Jadalannagari, S., Chaff, J. T., Velez, J., Joshipura, S. R., Kanellias, M., Simpson, A. P., Kerns, S. J., Ewart, L. C., Hegde, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.04.482954 · Cited by 4
Sakatis, M. Z., Norona, L. M., Karmel, J., Proctor, W. R., Sarr, F. H., Rana, P., Zane, D., Rae, J. M. C., Faber, S. C., Ravindra, K. C., et al. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00235 · Cited by 2
Self-citationMettler, L. G., Riede, J., Huth, F., Lohasz, C., Loskill, P., & Poller, B. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104242 · Cited by 2
Begriche, K., Massart, J., & Fromenty, B. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178879 · Cited by 2
From concept to context-of-use: A framework for Organ-on-Chip development
Araújo‐Gomes, N., Middelkamp, H. H. T., Loessberg-Zahl, J., Raaij, J. V. D. E., van der Meer, A. D., & Middendorp, S. (2026) · NAM journal. · doi:10.1016/j.namjnl.2026.100097 · Cited by 4
Investigating the link between drug metabolism and toxicity
Humphreys, W. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00027-1 · Cited by 3
Beers, J. L., Harvey, S. L., Geffert, R. M., Rushing, B. R., McRitchie, S., Sumner, S., & Jackson, K. D. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106126 · Cited by 3
Tran, A. T., Crawford, J. J., Mandal, D., Güney, T., & Karmel, J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch19 · Cited by 1
Cell painting in HepaRG cells: an interlaboratory reproducibility study
Sherer, E. A., Chen, W., Aberasturi, D. T., Sagar, K., Li, Y., Sutake, Z., Xu, J., Harris, F. R., Harrill, J., & LaRocca, J. L. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf139 · Cited by 1
Sati, P., Ali, R., Verma, M., Tiwari, N., Verma, S. K., & Sivakumar, S. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202503454 · Cited by 2
Road map for primary hepatocyte qualification in human liver organ models
Varmazyad, M., Gavlock, D. C., Castiglione, M. W., DeBiasio, R., LaRocca, G. M., Reese, C. E., Vernetti, L. A., Schurdak, M. E., Stern, A. M., Taylor, D. L., et al. (2026) · BMC Methods · doi:10.1186/s44330-026-00058-7 · Cited by 2
“More critically, the current state of MPS platforms lacks standardized, rigorous criteria for cell selection, which limits inter-laboratory reproducibility and hampers broader adoption of these platforms for consistent and meaningful biological insights [18].”
Engineering strategies for the clinical translation of organoids
Liao, L., Meng, Y., Shi, Y., Wang, B., Liu, C., Qiao, W., & Shen, J. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.03.049 · Cited by 4
Yu, Y., Zhong, H., Niu, Q., Zhao, M., Li, B., & Zhou, X. (2025) · Human & Experimental Toxicology · doi:10.1177/09603271251350797 · Cited by 1
“22 In the 3D model, ALB and UN levels showed an increasing trend, indicating the increasing hepatic functions (synthesis and metabolism) of the model.”
Toxicity Testing In Vitro. Regulatory Aspects
von Keutz, E. (2021) · Springer eBooks · doi:10.1007/978-3-642-36206-4_35-2 · Cited by 1
Toxicity Testing In Vitro: Regulatory Aspects
von Keutz, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-57499-4_35 · Cited by 1
IND04-01 Modernizing drug discovery & development with organ-chip technology
Berdichevski, S. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.07.241
How to reduce risk of drug induced liver toxicity from the beginning
Gan, J., He, K., & Humphreys, W. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00010-6 · Cited by 1
Self-citationOdanga, J. J., Gianulis, E. C., Whaley, L., LeCluyse, E. L., Presnell, S. C., & Weaver, J. R. (2023) · doi:10.3791/65992-v
Talari, A. C. S., Sbordoni, R., Hoti, V., Patel, I. I., Martin, F. L., Raza, A., & Llabjani, V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.12.607396
“6D) and was consistently above the human level threshold (>56 µg/million/hepatocytes) for 14 days in both conditions (39).”
BackgroundInfluentialLivoti, L. A., Sison-Young, R. L. C., Reddyhoff, D., Fisher, C. P., Gardner, I. B., Díaz-Nieto, R., Goldring, C. E., & Copple, I. M. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae164
Talari, A. C. S., Sbordoni, R., Hoti, V., Jalil, T., Patel, I. I., Martin, F. L., Raza, A., & Llabjani, V. (2025) · Research Square · doi:10.21203/rs.3.rs-6228265/v1
Talari, A. C. S., Sbordoni, R., Hoti, V., Jalil, T., Patel, I. I., Martin, F. L., Raza, A., & Llabjani, V. (2025) · In vitro models · doi:10.1007/s44164-025-00089-4 · Cited by 1
“Nonetheless, despite their albumin production, rat-derived hepatocytes cannot be considered to be as human-relevant as PHH [39].”
InfluentialTan, S., Yang, Y., Cai, Y., Pu, Y., Gu, Z., & Zhang, J. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117576 · Cited by 1
Liver-on-a-Chip: Searching for a Balance Between Biomimetics and Functionality
Murashko, A. V., Golubchikov, D. O., Smirnova, O. A., Oleynichenko, K., Nesterova, A., Vosough, M., Svistunov, A., Shpichka, A. I., & Timashev, P. (2026) · Biosensors · doi:10.3390/bios16040191
“Since the liver is one of the key players in drug metabolism, liver-mimicking models have the highest priority [8,9].”
Alternatives to animal models in gastroenterology and hepatology research
Gardey, E., Geisler, A. R., Löser, A., Stallmach, A., Kipp, A. P., Lorkowski, S., & Witt-Wallert, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789616
“Using liver-on-chip models for drug screening provides a more predictive method of assessing hepatotoxicity and therapeutic efficacy than traditional static cultures or animal models (Baudy et al., 2020).”
Messelmani, T. (2023) · theses.fr (ABES) · doi:10.70675/9a8f7a80zb4ebz4faczb395zff9d3d7ddeac
Engineering ethical test systems: Tissue-engineered and in vitro alternatives to in vivo experiments
Sanattalab, E., Zourazema, S., Zendeh, Z., Kaya, K., Çeçen, B., & Kozacı, L. D. (2026) · NAM journal. · doi:10.1016/j.namjnl.2026.100094 · Cited by 2
Deng, B., Ma, Y., Huang, W. Y., Xian, X., Ding, Y., Lu, Y., Yang, Y., Guo, W., Mao, L., Wang, X., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed7050
“2M) ( 25 ).”
Zhang, F., Zhou, Y., Ding, D., Zhang, F., Xiao, R., & Ai, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.15.732231
“…higher fidelity 3D microphysiological systems, including recent human liver organoid and liver-on-chip platforms, improve this to AUROC ∼ 0.75 [5, 7, 27, 35, 39, 43, 49, 51, 78] but at an order of magnitude higher per compound cost in reagents, procurement, and assay time, and a single…”
InfluentialBello, A., Sule, Z., Musa, I., Adeyemi, G., & Youssef, A. (2026) · Pharmacophore · doi:10.51847/0rccab9zhh
Liver-on-a-chip: Applications for clinical modeling of liver disease using microscale systems
Brooks, N. M., Peczak, A., & Schwartz, R. E. (2026) · Hepatology · doi:10.1097/hep.0000000000001829
Szabó, E., Telbisz, Á., Erdei, Z., Farkas, K., Homolya, L., Sarkadi, B., & Apáti, Á. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100157 · Cited by 1
Kang, J., Jin, H., Kim, K. H., Shin, D., Shin, D., Moon, H., & Kim, K.-T. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.6c03280
Negi, C. K., Chan, C. L. T., Tsai, H.-H. D., Alshammari, I., Sakolish, C., Chiu, W. A., Hewitt, P. G., Ferguson, S., Villenave, R., Bitounis, D., et al. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag114
“Among the organs that are of primary focus for such advances is the liver (Baudy et al. 2020; Kang et al. 2024), and specifically DILI which remains one of the leading causes of late-stage attrition in drug development and post-market withdrawals.”
Self-citationSoheili, M., Kohan, B. G., Rastegar, L., Moradi, Y., & Kohan, H. G. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2026.16454
“Notably, the Liver-Chip met IQ qualification guidelines, including the ability to distinguish between toxic drugs and their structurally related non-toxic analogs, a key criterion for regulatory acceptance [11, 41].”
InfluentialKamei, K. (2026) · Communications Biology · doi:10.1038/s42003-026-10887-5
Liver‐on‐Chip Models as Miniaturized Platforms for In Vitro Hepatotoxicity Testing
Sahoo, S., & Bishi, D. K. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70435
Metadata
- Authors
- Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Springhouse (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Bristol-Myers Squibb (United States) (US)
- F. Hoffmann-La Roche AG (CH)
- Sanofi (United States) (US)
- AbbVie (United States) (US)
- AbbVie, Inc.
- Genentech (US)
- Corresponding author
- Baudy, Andreas R.
- ORCID
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 20
- Issue
- 2
- Pages
- 215-225
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- OpenAlex
- W2990102938
- Cited by
- 150
- References
- 94
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 27 · 2020: 9
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lab on a Chip (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- liver-on-a-chip, liver injury, hepatotoxicity, model characterization, model benchmarking, key performance indicators, in vitro liver models, drug metabolism, species differences in drug metabolism, drug development
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Liver, Risk Assessment, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.